Over the past decades, the treatment options for ER+ breast cancer have improved dramatically, with patients now likely to receive the ER modulator tamoxifen as a first line agent in the pre-menopausal setting [1], or fulvestrant as a second-line agent in locally advanced and metastatic breast cancer [2]. This evidence concerns the gene ESR1 and breast carcinoma.